Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 2 |
2023 | 2 |
2024 | 1 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
arroju v[au]
(3 results)?
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2203632. doi: 10.1080/21645515.2023.2203632. Epub 2023 Apr 27.
Hum Vaccin Immunother. 2023.
PMID: 37113012
Free PMC article.
Clinical Trial.
Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.
Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla RR, Suneetha PV, Turaga K, Kyasani M, Manoharan SK, Adabala S, Sri Javvadi A, Medigeshi G, Singh J, Shaman H, Binayke A, Zaheer A, Awasthi A, Narang M, Nanjappa P, Mahantshetti N, Swarup Garg B, Pandey AK.
Thuluva S, et al. Among authors: yerroju v.
Vaccine. 2022 Nov 22;40(49):7130-7140. doi: 10.1016/j.vaccine.2022.10.045. Epub 2022 Oct 31.
Vaccine. 2022.
PMID: 36328879
Clinical Trial.
Item in Clipboard
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials.
Thuluva S, Paradkar V, Gunneri SR, Yerroju V, Mogulla R, Turaga K, Kyasani M, Manoharan SK, Medigeshi G, Singh J, Shaman H, Singh C, Rao A V.
Thuluva S, et al. Among authors: yerroju v.
EBioMedicine. 2022 Sep;83:104217. doi: 10.1016/j.ebiom.2022.104217. Epub 2022 Aug 12.
EBioMedicine. 2022.
PMID: 35970020
Free PMC article.
Clinical Trial.
Item in Clipboard
A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9-12 month old healthy infants.
Thuluva S, Gunneri S, Turaga K, Mogulla RR, Yerroju V, Peta K, Suneetha PV, Matur RV.
Thuluva S, et al. Among authors: yerroju v.
Contemp Clin Trials Commun. 2023 Nov 22;36:101232. doi: 10.1016/j.conctc.2023.101232. eCollection 2023 Dec.
Contemp Clin Trials Commun. 2023.
PMID: 38058513
Free PMC article.
Item in Clipboard
Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
Matur RV, Thuluva S, Gunneri S, Yerroju V, Reddy Mogulla R, Thammireddy K, Paliwal P, Mahantshetty NS, Ravi MD, Prashanth S, Verma S, Narayan JP.
Matur RV, et al. Among authors: yerroju v.
Vaccine. 2024 Apr 17:S0264-410X(24)00362-1. doi: 10.1016/j.vaccine.2024.03.056. Online ahead of print.
Vaccine. 2024.
PMID: 38637211
Item in Clipboard
Cite
Cite